Skip to main content

Yolanda Cámara Navarro

Institutions of which they are part

Main researcher
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Yolanda Cámara Navarro

Institutions of which they are part

Main researcher
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Projects

Identificación de factores reguladores de la función y estabilidad del complejo respiratorio mitocondrial I: explorando nuevas oportunidades terapéuticas (TARGETCOMPLEX-I)

IP: Yolanda Cámara Navarro
Collaborators: Elena García Arumí, Javier Francisco Ramón Pasías, Andrea Férriz Gordillo, Izaskun Izagirre Urizar
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 275000
Reference: PID2023-147668OB-I00
Duration: 01/09/2024 - 31/12/2027

Ministerio de Ciencia

Study of the in vivo role of NDUFA10 beyond respiratory complex I assembly: a possible link between oxidative metabolism and nucleotide homeostasis

IP: Yolanda Cámara Navarro
Collaborators: Izaskun Izagirre Urizar
Funding agency: Fundació Institut de Recerca HUVH
Funding: 102820.06
Reference: VHIR-PHD-2023-011
Duration: 05/02/2024 - 04/02/2028

Estudi de malalties neuromusculars i mitocondrials

IP: Ramon Martí Seves
Collaborators: Estudi de malalties neuromusculars i mitocondrials, Elena García Arumí, Yolanda Cámara Navarro, Mª Jesus Melia Grimal, Tomàs Pinós Figueras, Javier Francisco Ramón Pasías, Andrea Férriz Gordillo, Estudi de malalties neuromusculars i mitocondrials
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00894
Duration: 01/01/2022 - 30/06/2025

Deoxyribonucleosides as a therapy for mitochondrial DNA replication disorders: understanding therapeutic mechanisms and broadening the treatment to mutations in POLG and other related genes.

IP: Ramon Martí Seves
Collaborators: Yolanda Cámara Navarro, Javier Francisco Ramón Pasías
Funding agency: Fundació La Marató de TV3
Funding: 163812.5
Reference: 97/C/2020
Duration: 01/06/2021 - 31/12/2024

Related news

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The newly developed analytical workflow could in the future be introduced as a comprehensive diagnostic test for patients with mitochondrial diseases.

Related professionals

Carmen Roncal Mancho

Carmen Roncal Mancho

Postdoctoral researcher
Neurovascular Diseases
Read more
Fernando Clau Terre

Fernando Clau Terre

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Lydia Dux-Santoy Hurtado

Lydia Dux-Santoy Hurtado

Postdoctoral researcher
Cardiovascular Diseases
Read more
Gloria Mª Fraga Rodriguez

Gloria Mª Fraga Rodriguez

Senior researcher
Kidney Physiopathology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.